Mereo BioPharma Group plc (NASDAQ:MREO – Get Free Report) CEO Denise Scots-Knight sold 28,611 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total transaction of $127,891.17. Following the sale, the chief executive officer now directly owns 868,967 shares of the company’s stock, valued at $3,884,282.49. The sale was disclosed in a document filed with the SEC, which is available through this link.
Denise Scots-Knight also recently made the following trade(s):
- On Tuesday, June 25th, Denise Scots-Knight sold 40,712 shares of Mereo BioPharma Group stock. The shares were sold at an average price of $3.69, for a total transaction of $150,227.28.
Mereo BioPharma Group Price Performance
Shares of Mereo BioPharma Group stock traded up $0.22 during mid-day trading on Monday, reaching $4.50. 805,063 shares of the stock traded hands, compared to its average volume of 902,555. Mereo BioPharma Group plc has a fifty-two week low of $3.64 and a fifty-two week high of $5.02. The business has a 50-day moving average of $4.21 and a 200 day moving average of $3.61.
Institutional Trading of Mereo BioPharma Group
Analysts Set New Price Targets
MREO has been the subject of several research analyst reports. Leerink Partners lifted their target price on Mereo BioPharma Group from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, June 20th. Baird R W upgraded Mereo BioPharma Group to a “strong-buy” rating in a research note on Thursday, June 13th. Robert W. Baird initiated coverage on shares of Mereo BioPharma Group in a report on Thursday, June 13th. They issued an “outperform” rating and a $8.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Monday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $7.50.
Check Out Our Latest Stock Analysis on MREO
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
Recommended Stories
- Five stocks we like better than Mereo BioPharma Group
- Breakout Stocks: What They Are and How to Identify Them
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Conference Calls and Individual Investors
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Use the MarketBeat Excel Dividend Calculator
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.